25 completed. 25 Phase 1, 7 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 25 | Completed 25 |
| Phase 2 | 7 | Completed 7 |
Follow SARS-CoV-2: new trials by email Literature Review of SARS-CoV-2 trials Research Report on SARS-CoV-2
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of VXCO-100, a SARS-CoV Candidate Vaccine, in Adults in the Republic of South Africa VXCO-100, COVID-19 mRNA vaccine - SARS-CoV, SARS-CoV-2 | Phase 1 | Completed | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 130 | 2023-08-04 | 2024-12-10 |
| Study of VXCO-100, a SARS-CoV Candidate Vaccine in Healthy Adults in the United States VXCO-100 - SARS-CoV, SARS-CoV-2 | Phase 1 | Completed | Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company | 121 | 2023-05-11 | 2024-12-10 |
| A Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy Adults Influenza Vaccine 1, mRNA-1083.1, mRNA-1083.2 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 1758 | 2023-04-14 | 2025-12-23 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1045 (Influenza and Respiratory Syncytial Virus [RSV]) or mRNA-1230 (Influenza, RSV, and Severe Acute Respiratory Syndrome Coronavirus 2 [SARS-CoV-2]) Vaccine in Adults 50 to 75 Years Old mRNA-1010, mRNA-1345, mRNA-1273.214 - SARS-CoV-2, Influenza | Phase 1 | Completed | ModernaTX, Inc. | 392 | 2022-10-14 | 2024-03-08 |
| Safety and Immunogenicity Study of a Booster Dose of the Investigational CV0501 mRNA COVID-19 Vaccine in Adults at Least 18 Years Old CV0501 (3 μg), CV0501 (6 μg), CV0501 (12 μg) - COVID-19, SARS-CoV-2 | Phase 1 | Completed | GlaxoSmithKline | 185 | 2022-08-12 | 2025-02-21 |
| A Study of Modified mRNA Vaccines in Healthy Adults mRNA-1273, mRNA-1010, mRNA-1345 - SARS-CoV-2, Seasonal Influenza | Phase 1 | Completed | ModernaTX, Inc. | 308 | 2022-05-24 | 2026-03-12 |
| Evaluate the Safety and Immunogenicity of a SARS-CoV-2 mRNA Vaccine Booster SARS-CoV-2 mRNA vaccine (RBMRNA-405), CoronaVac® - SARS-CoV-2 | Phase 1 | Completed | Argorna Pharmaceuticals Co., LTD | 60 | 2022-05-16 | 2024-03-25 |
| A Safety, Reactogenicity, and Immunogenicity Study of mRNA-1073 (COVID-19/Influenza) Vaccine in Adults 18 to 75 Years Old mRNA-1073, mRNA-1010, mRNA-1273 - SARS-CoV-2, Influenza | Phase 1 / Phase 2 | Completed | ModernaTX, Inc. | 550 | 2022-05-13 | 2024-02-28 |
| Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19 COVI-VAC - COVID-19, SARS-CoV-2 | Phase 1 | Completed | Codagenix, Inc | 20 | 2022-04-14 | 2023-01-13 |
| Safety and Immune Response of Adjuvanted SARS-CoV-2 (COVID-19) Beta Variant RBD Recombinant Protein (DoCo-Pro-RBD-1 + MF59®) and mRNA (MIPSCo-mRNA-RBD-1) Vaccines in Healthy Adults Adjuvanted SARS-CoV-2 beta variant RBD recombinant protein vaccine (DoCo-Pro-RBD-1 + MF59), SARS-CoV-2 beta variant RBD mRNA vaccine, Normal Saline - SARS-CoV-2 | Phase 1 | Completed | University of Melbourne | 76 | 2022-04-05 | 2023-05-15 |
| Safety, Reactogenicity, and Immunogenicity Trial of CV2CoV mRNA Vaccine Against SARS-CoV-2 in Seropositive Adult Participants CV2CoV (2 µg), CV2CoV (4 µg), CV2CoV (8 µg) - COVID-19, SARS-CoV-2 | Phase 1 | Completed | GlaxoSmithKline | 99 | 2022-03-24 | 2024-08-12 |
| AZD7442 Pharmacokinetics, Pharmacodynamics, and Safety Evaluation in Pediatrics AZD7442 - SARS-CoV-2 | Phase 1 | Completed | AstraZeneca | 46 | 2022-03-21 | 2025-04-18 |
| Study of Self-Amplifying Messenger Ribonucleic Acid (samRNA) Vaccines Against COVID-19 in Healthy Adults and People Living With Human Immunodeficiency Virus (HIV) GRT-R912, samRNA-Spikebeta-TCE11, GRT-R914, samRNA-Spikebeta-TCE9, GRT-R918, samRNA-SpikeOmicron-N-TCE11 - COVID-19, SARS-CoV-2 | Phase 1 | Completed | Gritstone bio, Inc. | 342 | 2022-02-28 | 2024-03-12 |
| A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study. Sodium Chloride, NDV-HXP-S IN low dose, NDV-HXP-S IM low dose - SARS-CoV-2 | Phase 1 | Completed | Sean Liu | 35 | 2022-02-09 | 2025-04-17 |
| A Phase I/II Study to Evaluate a SARS-CoV-2 mRNA Vaccine in Healthy Adults RBMRNA-176, Placebo - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | Argorna Pharmaceuticals Co., LTD | 480 | 2022-01-08 | 2024-01-10 |
| A Clinical Trial of a Prophylactic Plasmid DNA Vaccine for COVID-19 [Covigenix VAX-001] in Adults Covigenix VAX-001 placebo, Covigenix VAX-001 - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | Entos Pharmaceuticals Inc. | 268 | 2021-04-07 | 2024-02-20 |
| A Study to Evaluate Safety, Reactogenicity, and Immunogenicity of mRNA-1283 and mRNA-1273 Vaccines in Healthy Adults Between 18 Years and 55 Years of Age to Prevent COVID-19 mRNA-1283, mRNA-1273, Placebo - SARS-CoV-2 | Phase 1 | Completed | ModernaTX, Inc. | 104 | 2021-03-11 | 2023-08-01 |
| Safety and Immunogenicity of GX-19N, a COVID-19 Preventive DNA Vaccine in Elderly Individuals GX-19N - SARS-CoV-2 | Phase 1 | Completed | Genexine, Inc. | 30 | 2021-02-16 | 2024-03-01 |
| GLS-5310 Vaccine for the Prevention of SARS-CoV-2 (COVID-19) GLS-5310, Placebo - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | GeneOne Life Science, Inc. | 171 | 2020-12-31 | 2025-09-03 |
| Safety and Immunogenicity Study of GX-19N, a COVID-19 Preventive DNA Vaccine in Healthy Adults GX-19N, Placebo - SARS-CoV-2 | Phase 1 / Phase 2 | Completed | Genexine, Inc. | 185 | 2020-12-30 | 2025-08-20 |
Showing 20 of 25. Sign in to see all of them.
COVID-19 (17) · Coronavirus Infections (8) · Virus Diseases (5) · Influenza, Human (4) · Severe Acute Respiratory Syndrome (3) · Acquired Immunodeficiency Syndrome (1) · Cytomegalovirus Infections (1)
Infections (19) · RNA Virus Infections (19) · Respiratory Tract Diseases (19) · Respiratory Tract Infections (19) · Coronaviridae Infections (18) · Nidovirales Infections (18) · Lung Diseases (17) · Pneumonia (17) · Pneumonia, Viral (17) · Virus Diseases (14) · Coronavirus Infections (10) · Orthomyxoviridae Infections (4) · Blood-Borne Infections (1) · Communicable Diseases (1) · DNA Virus Infections (1)
2019-nCoV Vaccine mRNA-1273 (3) · CVnCoV COVID-19 vaccine (3) · mRNA-1010 influenza vaccine (3) · GX-19N vaccine (2) · Saline Solution (2) · mRNA-1345 respiratory syncytial virus vaccine (2) · ADM03820 (1) · BNT162 Vaccine (1) · Baiya SARS-CoV-2 VAX COVID-19 vaccine (1) · COVI-VAC (1) · CV0501 COVID-19 vaccine (1) · GLS-5310 vaccine (1) · MF59 oil emulsion (1) · Methylene Blue (1) · NDV-HXP-S COVID-19 vaccine (1)
ModernaTX, Inc. (5) · Argorna Pharmaceuticals Co., LTD (2) · Genexine, Inc. (2) · GlaxoSmithKline (2) · Vaccine Company, Inc, a wholly owned subsidiary of Eli Lilly and Company (2) · Alachua Government Services, Inc. (1) · Arcturus Therapeutics, Inc. (1) · AstraZeneca (1) · BioNTech SE (1) · Codagenix, Inc (1) · CureVac (1) · Entos Pharmaceuticals Inc. (1) · GeneOne Life Science, Inc. (1) · Gritstone bio, Inc. (1) · I.M. Sechenov First Moscow State Medical University (1)
United States (11) · Australia (3) · China (3) · South Africa (3) · South Korea (3) · United Kingdom (3) · Belgium (2) · Germany (2) · Brazil (1) · Burkina Faso (1) · Canada (1) · Philippines (1) · Russia (1) · Senegal (1) · Singapore (1)
Jun Yong Choi, MD (2) · Angela Branche, MD (1) · Anusha Nana, BPharm (1) · Artem A. Shiryaev, Ph.D. (1) · Elizabeth Martin, DO (1) · Glenda Gray, MBChB, FC (1) · Igor V. Reshetov, Prof. (1) · Jenny Low Guek Hong, MD (1) · Joakem Tazanu Fossung (1) · JungWon Woo, Ph.D. (1) · Justin Ortiz, MD, MS (1) · Mbalizethu Mntambo, MBChB (1) · Nadine Rouphael, MD (1) · Prof. Terry Nolan (1)
PMID 34473343, PMID 35156068, PMID 35771353, PMID 36851196, PMID 37074202, PMID 38016322, PMID 39481241, PMID 39667115, PMID 40102593, PMID 40276503, PMID 41398408, PMID 41535296, PMID 41627968, PMID 41882056, PMID 42378814